GGrantIndex
← Leaderboards

Adam Lacy-Hulbert

Ohio State University

$10,392,021
Attributed
$12,894,401
Total exposure
14
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.7M · FY201025
$5M$3.8M$2.5M$1.3M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,894,401 · 14

By mechanism

R01$6,694,518 · 4
R33$3,029,177 · 2
R21$1,888,762 · 4
U01$772,657 · 1
R56$499,631 · 2
R13$9,656 · 1

Top collaborators

Most similar at Ohio State University

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsMediatingInfectionPreventResponsePathway InteractionsImmuneCytokineInflammationImmune SystemImmunityGenerationsChronicCell DeathUnited States National Institutes Of HealthInflammatoryBaseLeadGenesVirusSignal TransductionResistanceAffectRegulation

Grant awards (30)

LITAF regulation of membrane repair and inflammation$835,708
R01 · FY2025 · AI · contact PI
Regulation of Intestinal Immunity and Repair by Integrins$735,511
R01 · FY2025 · DK · contact PI
Immune Signatures and Clinical Outcomes in Acute Pancreatitis$680,769
R01 · FY2025 · DK
DCs as clinical targets of anti-integrin therapy in IBD$210,126
R21 · FY2025 · AI
LITAF regulation of membrane repair and inflammation$835,708
R01 · FY2024 · AI · contact PI
Regulation of Intestinal Immunity and Repair by Integrins$750,588
R01 · FY2024 · DK · contact PI
Immune Signatures and Clinical Outcomes in Acute Pancreatitis$656,955
R01 · FY2024 · DK
DCs as clinical targets of anti-integrin therapy in IBD$259,950
R21 · FY2024 · AI
Regulation of TLR signaling in anti-commensal B cell responses and mucosal inflammation$216,625
R21 · FY2024 · AI · contact PI
Immune Signatures and Clinical Outcomes in Acute Pancreatitis$757,597
R01 · FY2023 · DK
LITAF regulation of cell death and inflammatory responses$299,631
R56 · FY2023 · AI · contact PI
Regulation of TLR signaling in anti-commensal B cell responses and mucosal inflammation$259,950
R21 · FY2023 · AI · contact PI
alpha v integrin regulation of B cell tolerance$200,000
R56 · FY2021 · AI · contact PI
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis$510,000
R33 · FY2019 · AI · contact PI
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis$510,000
R33 · FY2018 · AI · contact PI
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis$510,000
R33 · FY2017 · AI · contact PI
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease$486,288
R33 · FY2016 · AI
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis$261,000
R21 · FY2016 · AI · contact PI
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease$499,889
R33 · FY2015 · AI
Dendritic Cell Control of Intestinal T Cell Responses$371,925
R01 · FY2015 · DK · contact PI
Identification of Host Drug Development Targets in Influenza Using Transposon Mutagenesis$217,500
R21 · FY2015 · AI · contact PI
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease$513,000
R33 · FY2014 · AI
Dendritic Cell Control of Intestinal T Cell Responses$371,925
R01 · FY2014 · DK · contact PI
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease$248,902
R21 · FY2013 · AI
Dendritic Cell Control of Intestinal T Cell Responses$226,615
R01 · FY2013 · DK · contact PI
Dendritic Cell Control of Intestinal T Cell Responses$114,832
R01 · FY2013 · DK · contact PI
Dendritic Cell Control of Intestinal T Cell Responses$356,385
R01 · FY2012 · DK · contact PI
Transposon Mutagenesis for Host-Target and Drug Discovery in Infectious Disease$214,709
R21 · FY2012 · AI
2011 Apoptotic Cell Recognition and Clearance Gordon Research Conference and Gord$9,656
R13 · FY2011 · AI · contact PI
Evolutionary lead optimization for immunotherapy of Marburg & Ebola viruses$772,657
U01 · FY2010 · AI · contact PI